Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Fig. 4

Mutated NRASQ61K causes ALK inhibitor resistance in ectopic expression model. a Ectopic expression of mutated NRAS (NRASQ61K) measured using a mutation specific qPCR without tetracycline treatment; values represent mean ± SD, n = 3. b Western blot analysis of total NRAS indicates slightly increased NRAS protein levels in SH-SY5Y TR NRASQ61K clones without induction with tetracycline. Note that the antibody is not mutation-specific, but detects both, ectopically expressed mutant NRAS as well as endogenously expressed wildtype NRAS. c Cell viabilities of SH-SY5Y TR NRASQ61K clones and empty vector control were assessed during ALK inhibitor treatment with ceritinib or lorlatinib indicating an ALKi resistant phenotype; values represent mean ± SD, n = 3

Back to article page